Aptinyx discovers and develops
innovative therapies for
challenging disorders of the brain and
nervous system.

nerve 650

Aptinyx's proprietary compounds modulate
the NMDA receptor,
a critical regulator
involved in nerve cell
communication.

Aptinyx seeks to leverage its experience and
track record of success to rapidly advance promising therapies in development for patients in need.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that work through a novel mechanism: modulation of NMDA receptors to enhance communication between neural cells.

Learn more about Aptinyx »

Latest News

October 15, 2019
Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience

September 30, 2019
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

September 26, 2019
Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925

September 4, 2019
Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors

August 21, 2019
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury

See all press and news »